期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 6, 期 6, 页码 306-307出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2009.69
关键词
-
类别
on the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据